Transthyretin allele selective UNA oligomers for gene silencing
US9982259B2 · kind B2 · utility
4Cited by
54References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2015 |
| Grant date | May 29, 2018 |
| Priority date | — |
| Expiry date | Mar 25, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/344
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides UNA oligomers for selectively inhibiting V30M TTR expression, which can be used in treating amyloidosis. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis by administering a UNA oligomer to a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.